Iron-based injection shows 84% disease control in early cancer trial

A Phase I trial in China of CNSI-Fe, an iron-based intratumoral injection inspired by wastewater treatment, controlled disease in 16 of 19 patients with advanced solid tumors. The objective response rate was 10.5%, and a 52-patient Phase II study is now underway at 10 Chinese hospitals.

• Disease control reached 16 of 19 patients, with tumor shrinkage in two
• Objective response rate was 10.5%; 16 participants had stage IV disease
• Injection pain affected 89.5% of patients, hypertension 52.6%
• Phase II trial with 52 patients is running at 10 Chinese hospitals